Mitapivat-Pyrukynd dosage adjustment and usage recommendations

Mitapivat-Pyrukynd is a pyruvate kinase (PK) activator, mainly used to treat hemolytic anemia in adults due to PK deficiency. This rare genetic disease causes chronic hemolysis due to a disorder in red blood cell metabolism, leading to symptoms such as anemia, jaundice, and splenomegaly. Metapival restores red blood cell metabolism, slows down the hemolysis process, and improves anemia symptoms by activating PK enzyme. In order to maximize efficacy and reduce side effects, the dosage adjustment and use of Metapival follow strict guidelines.

Treatment with mitava is usually initiated at a low dose to ensure that the patient tolerates the drug. The recommended starting dose is 5 mg twice daily. Next, the dose is gradually adjusted based on the patient's hemoglobin level and transfusion requirements. In clinical practice, hemoglobin and transfusion requirements are usually assessed every 4 weeks to determine whether a dose increase is needed.

Metapival tablets should be swallowed whole and should not be broken, crushed, chewed or dissolved. Patients can take it on an empty stomach or after a meal. If a dose of Metapival is missed within 4 hours, it should be taken as soon as possible. However, if you miss a dose for more than 4 hours, you should skip the dose and wait until the next scheduled dose to continue. Avoid taking a substitute dose at one time. Doing so can help reduce unnecessary side effects and adverse drug reactions.

Metapival must be used with a gradual dose reduction and avoidance of abrupt discontinuation, as acute hemolysis may occur upon abrupt discontinuation of therapy. When discontinuing the drug, patients should gradually reduce the dose under the guidance of a physician and closely monitor for signs of acute hemolysis or worsening anemia. Common symptoms of acute hemolysis include jaundice, scleral jaundice, darker urine, dizziness, fatigue, etc. Therefore, hemoglobin and hemolysis indicators should be checked regularly.

Reference materials:https://medlineplus.gov/druginfo/meds/a622018.html